Solid overall, bad return to office policy - Medical Director AstraZeneca Employee Review

3.0
Jan 31, 2024
Recommend
CEO approval
Business Outlook

Pros

Good science and portfolio. Some interesting work in digital and devices.

Cons

Terrible return to office policy. HR super inflexible.

Explore other reviews about AstraZeneca

5.0
Jun 25, 2026
Recommend
CEO approval
Business Outlook

Pros

Good products, great oncology pipeline

Cons

Global leaders moving to US that have limited understanding of US environment

4.0
Jun 29, 2026
Recommend
CEO approval
Business Outlook

Pros

Lots to learn with multiple launches and focus on AI

Cons

heavy middle layer slows down decision making

See reviews by: Helpful|Rating|Date|All